加强淋球菌抗菌药物监测计划（EGASP）：优化淋病治疗，2024年报告

Gonorrhoea treatment optimization, 2025 report Enhanced GonococcalAntimicrobial Surveillance Gonorrhoea treatment optimization, 2025 report Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP): gonorrhoea treatment optimization,2025 report ISBN 978-92-4-011729-7 (electronic version)ISBN 978-92-4-011730-3 (print version) © World Health Organization 2025 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0IGO licence (CCBY-NC-SA3.0IGO;https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes,provided the work is appropriately cited, as indicated below. In any use of this work, there should be nosuggestion that WHO endorses any specific organization, products or services. The use of the WHO logo isnot permitted. If you adapt the work, then you must license your work under the same or equivalent CreativeCommons licence. If you create a translation of this work, you should add the following disclaimer along with Any mediation relating to disputes arising under the licence shall be conducted in accordance with themediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation.Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP): gonorrhoeatreatment optimization, 2025 report. Geneva: World Health Organization; 2025. Licence:CCBY-NC-SA3.0IGO. Cataloguing-in-Publication (CIP) data.CIP data are available athttps://iris.who.int/. Sales, rights and licensing.To purchase WHO publications, seehttps://www.who.int/publications/book-orders. To submit requests for commercial use and queries on rights and licensing, seehttps://www.who.int/copyright. Third-party materials.If you wish to reuse material from this work that is attributed to a third party, such astables, figures or images, it is your responsibility to determine whether permission is needed for that reuse andto obtain permission from the copyright holder. The risk of claims resulting from infringement of any third- General disclaimers.The designations employed and the presentation of the material in this publicationdo not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of anycountry, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsedor recommended by WHO in preference to others of a similar nature that are not mentioned. Errors andomissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication.However, the published material is being distributed without warranty of any kind, either expressed or implied.The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be Contents Acknowledgementsiv Abbreviations 3 2. Methods 2.1Participating countries and settings2.2Patient enrolment2.3Specimen collection and testing procedures2.4Standardized data management2.5Data validation2.6Data analysis 3. Results3.1Global overview3.2Demographic, behavioural and clinical data3.2.1 Patient’s characteristics and exposure factors3.3Antimicrobial susceptibility data3.3.1 Laboratory data3.3.2 Antimicrobial susceptibility testing3.3.3 Trends in antimicrobial susceptibility, 2022–2024 4. Snapshots from the field4.1Extragenital sampling 5. Conclusions346. References37Annex 1. Treatments used for EGASP surveillance, 202439Annex 2. The outcome of treatment and follow-up for EGASP surveillance43 Acknowledgements The World Health Organization thanks the Member States and all our technical partners who supported thedevelopment and continued implementation of the WHO Enhanced Gonococcal Antimicrobial SurveillanceProgramme (EGASP). WHO gratefully acknowledges the contributions of the WHO Collaborating Centre forGonorrhoea and Other Sexually Transmitted Infections at Örebro University Hospital and Örebro University, WHO also acknowledges the financial support and technical contributions of the European Commission’sHealth Emergency Preparedness and Response Authority in strengthening gonorrhoea treatment optimizationefforts at the country, regional and global levels. The dedicated efforts of the health-care workers and partners at the local and national levels have made thiswork possible. WHO is grateful for the efforts of the following people. Overall coordination Ismail Maatouk led the development of this report with support from Phiona Vumbugwa and Daniel McCartney(Department of HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections) and Magnus Unemo(WHO Collaborating Centre for Gonorrhoea and Other Sexually